Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

• 主要な著者: Shanshan Hu (著者), Xiaorong Su (著者), Xun Deng (著者), Yong Wang (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide for T2D patients in China based on cost-utili...